Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron
Abstract Background Longitudinal estimates of long COVID burden during Omicron remain limited. This study characterized long-term impacts of COVID-19 and booster vaccination on symptoms, Health-Related Quality of Life (HRQoL), and Work Productivity Activity Impairment (WPAI). Methods Outpatients wit...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2023-07-01
|
| Series: | Journal of Patient-Reported Outcomes |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41687-023-00616-5 |
| _version_ | 1797769520608182272 |
|---|---|
| author | Manuela Di Fusco Xiaowu Sun Mary M. Moran Henriette Coetzer Joann M. Zamparo Mary B. Alvarez Laura Puzniak Ying P. Tabak Joseph C. Cappelleri |
| author_facet | Manuela Di Fusco Xiaowu Sun Mary M. Moran Henriette Coetzer Joann M. Zamparo Mary B. Alvarez Laura Puzniak Ying P. Tabak Joseph C. Cappelleri |
| author_sort | Manuela Di Fusco |
| collection | DOAJ |
| description | Abstract Background Longitudinal estimates of long COVID burden during Omicron remain limited. This study characterized long-term impacts of COVID-19 and booster vaccination on symptoms, Health-Related Quality of Life (HRQoL), and Work Productivity Activity Impairment (WPAI). Methods Outpatients with ≥ 1 self-reported symptom and positive SARS-CoV-2 test at CVS Health United States test sites were recruited between 01/31 and 04/30/2022. Symptoms, EQ-5D and WPAI were collected via online surveys until 6 months following infection. Both observed and model-based estimates were analyzed. Effect sizes based on Cohen’s d quantified the magnitude of outcome changes over time, within and between vaccination groups. Mixed models for repeated measures were conducted for multivariable analyses, adjusting for covariates. Logistic regression assessed odds ratio (OR) of long COVID between vaccination groups. Results At long COVID start (Week 4), 328 participants included 87 (27%) Boosted with BNT162b2, 86 (26%) with a BNT162b2 primary series (Primed), and 155 (47%) Unvaccinated. Mean age was 42.0 years, 73.8% were female, 26.5% had ≥ 1 comorbidity, 36.9% prior infection, and 39.6% reported ≥ 3 symptoms (mean: 3.1 symptoms). At Month 6, among 260 participants, Boosted reported a mean of 1.1 symptoms versus 3.4 and 2.8 in Unvaccinated and Primed, respectively (p < 0.001). Boosted had reduced risks of ≥ 3 symptoms versus Unvaccinated (observed: OR 0.22, 95% CI 0.10–0.47, p < 0.001; model-based: OR 0.36, 95% CI 0.15–0.87, p = 0.019) and Primed (observed: OR 0.29, 95% CI 0.13–0.67, p = 0.003; model-based: OR 0.59, 95% CI 0.21–1.65, p = 0.459). Results were consistent using ≥ 2 symptoms. Regarding HRQoL, among those with long COVID, Boosted had higher EQ-5D Utility Index (UI) than Unvaccinated (observed: 0.922 vs. 0.731, p = 0.014; model-based: 0.910 vs. 0.758, p-value = 0.038) and Primed (0.922 vs. 0.648, p = 0.014; model-based: 0.910 vs. 0.708, p-value = 0.008). Observed and model-based estimates for EQ-VAS and UI among Boosted were comparable with pre-COVID since Month 3. Subjects vaccinated generally reported better WPAI scores. Conclusions Long COVID negatively impacted HRQoL and WPAI. The BNT162b2 booster could have a beneficial effect in reducing the risk and burden of long COVID. Boosted participants reported fewer and less durable symptoms, which contributed to improve HRQoL and maintain WPAI levels. Limitations included self-reported data and small sample size for WPAI. |
| first_indexed | 2024-03-12T21:09:16Z |
| format | Article |
| id | doaj.art-b2b3fd0b3cb14cf0af5bdac630cc1afc |
| institution | Directory Open Access Journal |
| issn | 2509-8020 |
| language | English |
| last_indexed | 2024-03-12T21:09:16Z |
| publishDate | 2023-07-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Journal of Patient-Reported Outcomes |
| spelling | doaj.art-b2b3fd0b3cb14cf0af5bdac630cc1afc2023-07-30T11:16:43ZengSpringerOpenJournal of Patient-Reported Outcomes2509-80202023-07-017111610.1186/s41687-023-00616-5Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during OmicronManuela Di Fusco0Xiaowu Sun1Mary M. Moran2Henriette Coetzer3Joann M. Zamparo4Mary B. Alvarez5Laura Puzniak6Ying P. Tabak7Joseph C. Cappelleri8Health Economics and Outcomes Research, Pfizer IncCVS HealthPfizer IncCVS HealthPfizer IncField Medical Outcomes and Analytics, Pfizer IncMDSCA Vaccines, Pfizer IncCVS HealthStatistical Research and Data Science Center, Pfizer IncAbstract Background Longitudinal estimates of long COVID burden during Omicron remain limited. This study characterized long-term impacts of COVID-19 and booster vaccination on symptoms, Health-Related Quality of Life (HRQoL), and Work Productivity Activity Impairment (WPAI). Methods Outpatients with ≥ 1 self-reported symptom and positive SARS-CoV-2 test at CVS Health United States test sites were recruited between 01/31 and 04/30/2022. Symptoms, EQ-5D and WPAI were collected via online surveys until 6 months following infection. Both observed and model-based estimates were analyzed. Effect sizes based on Cohen’s d quantified the magnitude of outcome changes over time, within and between vaccination groups. Mixed models for repeated measures were conducted for multivariable analyses, adjusting for covariates. Logistic regression assessed odds ratio (OR) of long COVID between vaccination groups. Results At long COVID start (Week 4), 328 participants included 87 (27%) Boosted with BNT162b2, 86 (26%) with a BNT162b2 primary series (Primed), and 155 (47%) Unvaccinated. Mean age was 42.0 years, 73.8% were female, 26.5% had ≥ 1 comorbidity, 36.9% prior infection, and 39.6% reported ≥ 3 symptoms (mean: 3.1 symptoms). At Month 6, among 260 participants, Boosted reported a mean of 1.1 symptoms versus 3.4 and 2.8 in Unvaccinated and Primed, respectively (p < 0.001). Boosted had reduced risks of ≥ 3 symptoms versus Unvaccinated (observed: OR 0.22, 95% CI 0.10–0.47, p < 0.001; model-based: OR 0.36, 95% CI 0.15–0.87, p = 0.019) and Primed (observed: OR 0.29, 95% CI 0.13–0.67, p = 0.003; model-based: OR 0.59, 95% CI 0.21–1.65, p = 0.459). Results were consistent using ≥ 2 symptoms. Regarding HRQoL, among those with long COVID, Boosted had higher EQ-5D Utility Index (UI) than Unvaccinated (observed: 0.922 vs. 0.731, p = 0.014; model-based: 0.910 vs. 0.758, p-value = 0.038) and Primed (0.922 vs. 0.648, p = 0.014; model-based: 0.910 vs. 0.708, p-value = 0.008). Observed and model-based estimates for EQ-VAS and UI among Boosted were comparable with pre-COVID since Month 3. Subjects vaccinated generally reported better WPAI scores. Conclusions Long COVID negatively impacted HRQoL and WPAI. The BNT162b2 booster could have a beneficial effect in reducing the risk and burden of long COVID. Boosted participants reported fewer and less durable symptoms, which contributed to improve HRQoL and maintain WPAI levels. Limitations included self-reported data and small sample size for WPAI.https://doi.org/10.1186/s41687-023-00616-5COVID-19SARS-CoV-2COVID-19 symptomsLong COVIDBNT162b2Booster vaccine |
| spellingShingle | Manuela Di Fusco Xiaowu Sun Mary M. Moran Henriette Coetzer Joann M. Zamparo Mary B. Alvarez Laura Puzniak Ying P. Tabak Joseph C. Cappelleri Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron Journal of Patient-Reported Outcomes COVID-19 SARS-CoV-2 COVID-19 symptoms Long COVID BNT162b2 Booster vaccine |
| title | Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron |
| title_full | Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron |
| title_fullStr | Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron |
| title_full_unstemmed | Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron |
| title_short | Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron |
| title_sort | impact of covid 19 and effects of booster vaccination with bnt162b2 on six month long covid symptoms quality of life work productivity and activity impairment during omicron |
| topic | COVID-19 SARS-CoV-2 COVID-19 symptoms Long COVID BNT162b2 Booster vaccine |
| url | https://doi.org/10.1186/s41687-023-00616-5 |
| work_keys_str_mv | AT manueladifusco impactofcovid19andeffectsofboostervaccinationwithbnt162b2onsixmonthlongcovidsymptomsqualityoflifeworkproductivityandactivityimpairmentduringomicron AT xiaowusun impactofcovid19andeffectsofboostervaccinationwithbnt162b2onsixmonthlongcovidsymptomsqualityoflifeworkproductivityandactivityimpairmentduringomicron AT marymmoran impactofcovid19andeffectsofboostervaccinationwithbnt162b2onsixmonthlongcovidsymptomsqualityoflifeworkproductivityandactivityimpairmentduringomicron AT henriettecoetzer impactofcovid19andeffectsofboostervaccinationwithbnt162b2onsixmonthlongcovidsymptomsqualityoflifeworkproductivityandactivityimpairmentduringomicron AT joannmzamparo impactofcovid19andeffectsofboostervaccinationwithbnt162b2onsixmonthlongcovidsymptomsqualityoflifeworkproductivityandactivityimpairmentduringomicron AT marybalvarez impactofcovid19andeffectsofboostervaccinationwithbnt162b2onsixmonthlongcovidsymptomsqualityoflifeworkproductivityandactivityimpairmentduringomicron AT laurapuzniak impactofcovid19andeffectsofboostervaccinationwithbnt162b2onsixmonthlongcovidsymptomsqualityoflifeworkproductivityandactivityimpairmentduringomicron AT yingptabak impactofcovid19andeffectsofboostervaccinationwithbnt162b2onsixmonthlongcovidsymptomsqualityoflifeworkproductivityandactivityimpairmentduringomicron AT josephccappelleri impactofcovid19andeffectsofboostervaccinationwithbnt162b2onsixmonthlongcovidsymptomsqualityoflifeworkproductivityandactivityimpairmentduringomicron |